A Comparative Study of Current Medicaid Prescription Reimbursement (MACtEAC) with Prescription Reimbursement Based on a Competitive Market

Abstract
Many pharmacists have suggested that the current Maximum Allowable CostEstimated Acquisttion Cost (MACEAC) program has departed from its intended purpose of generating savings by taking full but fair advantage of the competitive marketplace. The objective of this study was to compare Medicaid prescription reimbursement under current MACEAC regulations with prescription reimbursement based on a competitive market. Data representing the top selling single source and multiple source drug products for nine states were analyzed. Results indicated thal the current MACEAC system of Medicaid reimbursement produced a small savings when compared to reimbursement based on a competitive market.

This publication has 0 references indexed in Scilit: